Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.
about
Defining post-operative pancreatitis as a new pancreatic specific complication following pancreatic resectionTargeting the mTOR signaling pathway in neuroendocrine tumorsSynergistic antitumor activities of docetaxel and octreotide associated with apoptotic-upregulation in castration-resistant prostate cancerLesion-based analysis of (18)F-FDG uptake and (111)In-Pentetreotide uptake by neuroendocrine tumors.Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysisPharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance.Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumorsThe expanding role of somatostatin analogs in the management of neuroendocrine tumors.Somatostatinergic systems: an update on brain functions in normal and pathological aging.Peptide receptor targeting in cancer: the somatostatin paradigm.Modulation of the adaptive response to stress by brain activation of selective somatostatin receptor subtypes.Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.The truncated isoform of somatostatin receptor5 (sst5TMD4) is associated with poorly differentiated thyroid cancer.The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) and the Role of Somatostatin analogs: A Case Series.Octreotide in combination with AT-101 induces cytotoxicity and apoptosis through up-regulation of somatostatin receptors 2 and 5 in DU-145 prostate cancer cells.Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy.Carcinoid heart disease: a guide for screening and timing of surgical interventionThe safety of available treatments options for neuroendocrine tumors.Neuroendocrine differentiation in castration-resistant prostate cancer: A case report.Effects of octreotide therapy in progressive head and neck paragangliomas: case series.Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.Molecular challenges of neuroendocrine tumors.Update in the Therapy of Advanced Neuroendocrine Tumors.Challenging Management of Neuroendocrine Tumor With Hepatic Metastasis and Carcinoid Heart Disease in a Child.Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines.Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas.
P2860
Q26739913-824FE922-C688-4270-ADE6-AA547C02B433Q26852089-ED0073BE-0E3F-4AB3-9661-179B7080AE97Q28540917-79E08FFC-A854-4414-BC7F-FEE56263D99EQ34573802-07B65A76-6C54-40EC-A72E-419A875EFF23Q34992833-147BD9C3-44AC-4814-AA57-1F7993D2D300Q35681825-9BA4F4DC-8900-40D4-A3AF-DF4EDB9574CDQ35695360-A9C9212E-5BD4-4C34-BB42-8332CC50EF4DQ35747137-52391CBF-1F5E-4F10-9477-C726804611C0Q36347272-313B96BF-E312-4DBE-9956-623EF98FA9C3Q36449496-6F3DA496-08A9-4FA9-BBE0-57C8B0E1743AQ36638046-6817BD98-6368-404E-8FD7-125D7F39244FQ36788491-3FD4466D-3FC0-4293-95A3-B2A555111EE8Q36916282-D6C02F53-B9A0-4F74-943C-AC265C1D69D7Q37499468-A4C5F550-9EF7-44B8-966B-B833435517C5Q38441413-2767A62E-5419-49E0-A383-889196FE1AE6Q38538085-1685BA42-A5AF-4854-BBBF-6A17EE4FA536Q38822225-48640F2E-B580-40BC-8CB0-3EE67F48719CQ39378866-EFB3C04C-2E1E-4BD9-9F8C-D31A7C990FBBQ39385108-F70E356D-12E1-4946-A9D0-452C9FD3B88BQ39433254-04D8A461-2338-4F49-B22D-E41384C2EE5BQ43147589-814E9956-F5CF-42F9-91C3-19664909DE87Q43755698-8B0BC2E6-C16F-4EE7-9C1A-7CFEC31CE587Q45071563-D8D461E4-A87C-4DBD-A5E4-6668175BAF28Q49875027-8D00E7D3-C978-48CE-8AA5-6BD38B8347AFQ49970741-65ACD526-89F7-41A2-A3CF-E9E7596419FFQ51366001-3A923714-CC9E-4939-97B1-4E861E0BAAD6Q52717640-90CF8AF2-6D32-45B6-B040-8489275A32BFQ52940698-BEC7B852-046B-4448-B0A0-8076D36A2A9A
P2860
Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Clinical review: Current scien ...... neuroendocrine tumor therapy.
@en
Clinical review: Current scien ...... neuroendocrine tumor therapy.
@nl
type
label
Clinical review: Current scien ...... neuroendocrine tumor therapy.
@en
Clinical review: Current scien ...... neuroendocrine tumor therapy.
@nl
prefLabel
Clinical review: Current scien ...... neuroendocrine tumor therapy.
@en
Clinical review: Current scien ...... neuroendocrine tumor therapy.
@nl
P2093
P356
P1476
Clinical review: Current scien ...... neuroendocrine tumor therapy.
@en
P2093
Charline Lasfargues
Christiane Susini
Corinne Bousquet
Delphine Vezzosi
Mounira Chalabi
Philippe Caron
Siham Moatassim Billah
Stéphane Pyronnet
P304
P356
10.1210/JC.2011-2088
P407
P577
2011-12-14T00:00:00Z